ChulaCov19 mRNA vaccine- Chulalongkorn University
Alternative Names: Bivalent ChulaCov19 BNA159.2; ChulaCov19 BNA159 vaccine; ChulaCov19- mRNA vaccine; ComvigenLatest Information Update: 28 Feb 2024
At a glance
- Originator Chulalongkorn University
- Developer BioNet-Asia; Chulalongkorn University; Technovalia; Thai Red Cross Society
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention, In volunteers) in Thailand (IM, Injection)
- 19 Jan 2023 Phase-II clinical trials in COVID-2019 infections (Prevention, In volunteers) in Australia (IM) (NCT05605470)
- 14 Dec 2022 Chulalongkorn University and Bionet asia initiates enrolment in a phase I trial for COVID-2019 infections (In Volunteers, Prevention) in Thailand (NCT05231369)